Hetero gets DCGI nod for Hepatitis C generic

G Naga Sridhar Hyderabad | Updated on January 11, 2018 Published on May 05, 2017

Drug maker Hetero has received approval for the generic version of Sofosbuvir and Velpatasvir combination drug from the Drug Controller-General of India.

The approved drug is a generic of Gilead’s Epclusa brand and is indicated for the treatment of chronic Hepatitis C genotype 1 to 6, the Hyderabad-based Hetero said in a release issued here on Friday.

It will be distributed and marketed in the domestic market under the brand 'Velasof’ by Hetero Healthcare.

"This product will be launched under a non-exclusive agreement with Gilead Science Inc, which allows it to manufacture and sell generic versions of its chronic Hepatitis C medicines in 101 developing countries,’’ the company said.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on May 05, 2017
This article is closed for comments.
Please Email the Editor